TF1 Polypeptide Stx2 Toxin Neutralization via Receptor Mimicry
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for infections caused by Shiga toxin-producing pathogens, such as Stx2, lack effective prophylactic or therapeutic options, with antibiotics often leading to drug-resistant strains and increased toxin release, and existing therapies like receptor-based polysaccharide compounds and antibody therapies facing development and safety challenges.
Innovation Solution
Development of a polypeptide, TF1, which specifically binds to Stx2, inhibiting its activity by blocking the toxin's binding to eukaryotic cell receptors, along with its modified versions and the gene encoding it, for use in treating Stx2-producing pathogens like Escherichia coli and Shigella dysenteriae.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If antibiotics are used to treat Stx-producing pathogen infections, then bacterial growth is inhibited, but toxin release increases and drug-resistant strains emerge
Solution Approach 1:
The patent uses a recombinant protein mimic of the Gb3 receptor as an intermediary substance that binds to Stx2 toxin, preventing direct interaction between the toxin and human cell receptors. This mediator approach neutralizes the toxin without requiring antibiotics, thus avoiding toxin release from bacterial lysis and preventing selection of drug-resistant strains.
Solution Approach 2:
The invention creates a recombinant protein that copies the structure and function of the Gb3 receptor (the natural toxin binding target). This copied receptor structure, expressed in E. coli as a soluble protein, serves as a decoy that mimics the original receptor's binding properties while being produced through genetic engineering rather than extraction from complex biological sources.
2Reliability
If receptor-based polysaccharide compounds are used to neutralize toxin, then binding affinity is achieved, but preparation complexity and side effects increase
Solution Approach 1:
The patent replaces the complex mechanical/extraction-based preparation of polysaccharide compounds from natural sources with a genetic engineering approach. The Gb3 receptor mimic is produced through recombinant DNA technology in E. coli, substituting complex chemical extraction and purification processes with microbial expression systems that yield soluble, purified protein directly.
Solution Approach 2:
The invention changes the physical state and solubility parameters of the receptor mimic by engineering it as a soluble protein rather than an insoluble membrane-bound polysaccharide. This parameter change from insoluble to soluble state simplifies purification and reduces preparation complexity while maintaining toxin-binding functionality.
3Reliability
If probiotics expressing receptor mimic are used for treatment, then toxin neutralization is achieved, but safety concerns arise
Solution Approach 1:
The patent extracts the essential functional element (the Gb3 receptor binding domain) from the complex probiotic system and isolates it as a standalone recombinant protein product. This extraction separates the therapeutic function from the probiotic vehicle, eliminating safety concerns associated with administering live or killed bacterial cells while preserving the toxin-neutralizing capability.
4Reliability
If monoclonal antibody therapy is used to block toxin binding, then neutralization is achieved, but production cost and complexity increase
Solution Approach 1:
The patent replaces expensive, complex monoclonal antibody production with a simpler, cheaper recombinant protein approach. The Gb3 receptor mimic can be produced in large quantities through bacterial expression systems at lower cost, serving as a disposable therapeutic agent that achieves the same neutralization function without the complexity of antibody manufacturing and quality control.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
TF1 effectively neutralizes Stx2 toxicity in vitro and in vivo, providing significant protection against Stx2-induced cytotoxicity and lethality, with a high binding affinity and dose-dependent inhibition, demonstrating potential as a safe and effective treatment option.
Implementation Method 1
TF1 specifically binds to Stx2, inhibiting its activity by blocking the toxin's binding to eukaryotic cell receptors
Data Source
AI summary
The present invention provides a polypeptide TF1 for inhibiting type-2 Shiga-toxin activity, an encoding gene for the same and use thereof. The present polypeptide is named TF1 (also known as P1); its amino acid sequence is shown in Sequence 1 in the sequence list. The polypeptide P1 can be prepared into medicine for preventing and/or treating diseases caused by type-2 Shiga toxin or the pathogens which produce type-2 Shiga toxin.